Oral bisphosphonate use in the elderly is not associated with acute kidney injury

Kidney International

Volumn 82, Issue 8, 2012, Pages 903-908

  Shih, Andrew W Y ^a   Weir, Matthew A ^a   Clemens, Kristin K ^a   Yao, Zhan ^b   Gomes, Tara ^b,c   Mamdani, Muhammad M ^b,c,d,e   Juurlink, David N ^b,c,d,e   Hird, Amanda ^e   Hodsman, Anthony ^a   Parikh, Chirag R ^f   Wald, Ron ^c,e   Cadarette, Suzanne M ^b,c   Garg, Amit X ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CREATININE;

ACUTE KIDNEY FAILURE; AGED; AGING; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG ADMINISTRATION ROUTE; DRUG SAFETY; DRUG USE; FEMALE; FRAGILITY FRACTURE; GLOMERULUS FILTRATION RATE; HOSPITAL DISCHARGE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION;

EID: 84867089856     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.227     Document Type: Article

References (45)

1. Carey JJ, Palomo L. Bisphosphonates and osteonecrosis of the jaw: innocent association or significant risk? Cleve Clin J Med 2008; 75: 871-879.
2. Wells GA, Cranney A, Peterson J et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008: CD003376.
3. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-1541.
4. Cranney A, Tugwell P, Adachi J et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23: 517-523.
5. Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 2006; 6: 307-312.
6. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003; 9: 2643-2658.
7. Holthofer H, Kretzler M, Haltia A et al. Altered gene expression and functions of mitochondria in human nephrotic syndrome. FASEB J 1999; 13: 523-532.
8. Hotta O, Inoue CN, Miyabayashi S et al. Clinical and pathologic features of focal segmental glomerulosclerosis with mitochondrial tRNALeu(UUR) gene mutation. Kidney Int 2001; 59: 1236-1243.
9. Sauter M, Julg B, Porubsky S et al. Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept? Am J Kidney Dis 2006; 47: 1075-1080.
10. Markowitz GS, Appel GB, Fine PL et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001; 12: 1164-1172.
11. Rogers MJ, Gordon S, Benford HL et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88: 2961-2978.
12. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996; 65: 241-269.
13. Barisoni L, Kriz W, Mundel P et al. The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 1999; 10: 51-61.
14. Rosen LS, Gordon D, Tchekmedyian NS et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004; 100: 2613-2621.
15. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468.
16. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 2008; 74: 1385-1393.
17. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003; 349: 1676-1679; discussion 1676-1679.
18. FDA Drug Safety Communication. New contraindication and updated warning on kidney impairment for Reclast (zoledronic acid) [Internet]. 2011 Sept [cited 6 September 2011]. Available from: http://www.fda.gov/Drugs/DrugSafety/ ucm270199.htm.
19. Gertz BJ, Holland SD, Kline WF et al. Clinical pharmacology of alendronate sodium. Osteoporos Int 1993; 3(Suppl 3): S13-S16.
20. Pascual J, Torrealba J, Myers J et al. Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate. Osteoporos Int 2007; 18: 1435-1438.
21. Pena de la Vega L, Fervenza FC, Lager D et al. Acute granulomatous interstitial nephritis secondary to bisphosphonate alendronate sodium. Ren Fail 2005; 27: 485-489.
22. Zazgornik J, Grafinger P, Biesenbach G et al. Acute renal failure and alendronate. Nephrol Dial Transplant 1997; 12: 2797-2798.
23. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344-1352.
24. Chesnut IC, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-1249.
25. Fraser LA, Ioannidis G, Adachi JD et al. Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study. Osteoporos Int 2011; 22: 789-796.
26. Papaioannou A, Morin S, Cheung AM et al. Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010; 182: 1864-1873.
27. Yanik B, Bavbek N, Yanik T et al. The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women. Ren Fail 2007; 29: 471-476.
28. Waikar SS, Wald R, Chertow GM et al. Validity of international classification of diseases, ninth revision, clinical modification codes for acute renal failure. J Am Soc Nephrol 2006; 17: 1688-1694.
29. Juurlink DN, Preyra C, Croxford R et al. Canadian institute for health information discharge abstract database: a Validation Study. 2006.
30. Hsu CY, Ordonez JD, Chertow GM et al. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int 2008; 74: 101-107.
31. Ali T, Khan I, Simpson W et al. Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol 2007; 18: 1292-1298.
32. Statistics Canada C. Population by sex and age group, by province or territory. Table 051-0001. [Internet]. 2011 [cited 14 February 2011]. Available from: http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/demo31a-eng. htm.
33. Levy AR, O'Brien BJ, Sellors C et al. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 2003; 10: 67-71.
34. Alter DA, Naylor CD, Austin P et al. Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction. N Engl J Med 1999; 341: 1359-1367.
35. Austin PC, Mamdani MM, Tu K et al. Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women's Health Initiative Study. JAMA 2003; 289: 3241-3242.
36. Juurlink DN, Mamdani M, Kopp A et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289: 1652-1658.
37. Melo M, Qiu F, Sykora K et al. Persistence with bisphosphonate therapy in older people. J Am Geriatr Soc 2006; 54: 1015-1016.
38. Bellomo R, Ronco C, Kellum JA et al. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-R212.
39. Mehta RL, Kellum JA, Shah SV et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31.
40. Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int 2008; 73: 538-546.
41. Chertow GM, Burdick E, Honour M et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 16: 3365-3370.
42. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
43. Austin P. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Comm Stat Simulation Computation 2009; 38: 1228-1234.
44. Mamdani M, Sykora K, Li P et al. Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ 2005; 330: 960-962.
45. Garg AX, Mamdani M, Juurlink DN et al. Identifying individuals with a reduced GFR using ambulatory laboratory database surveillance. J Am Soc Nephrol 2005; 16: 1433-1439.